フルテキストURL K0005440_other1.pdf
著者 Hiroshi, Umemura| Yamasaki, Osamu| Kaji, Tatsuya| Otsuka, Masaki| Asagoe, Kenji| Takata, Minoru| Iwatsuki, Keiji|
抄録 With the recent development of novel molecular targeted drugs for advanced stage malignant melanoma (MM), including RAF and mitogen-activated protein kinase kinase inhibitors and immune checkpoint blockers, the early detection of relapse is important for managing patients with MM. In this study, we retrospectively analyzed two conventional serum biomarkers, 5-S-cysteinyl-dopa and lactate dehydrogenase, in patients with MM (n = 140) who were treated at a single Japanese institute from June 2007 to June 2015. At the initial hospital visit, serum 5-S-cysteinyl-dopa levels were significantly increased in patients with stages III (n = 38) and IV (n = 20) MM compared with patients with stages 0-II (n = 62) MM. In addition, in patients with stages III and IV MM, serum 5-S-cysteinyl-dopa levels of more than 15.0 nmol/L at initial hospital visit correlated with a poor prognosis. In 11 of 14 patients whose disease progressed during follow up (mostly from stages III-IV), serum 5-S-cysteinyl-dopa levels exceeded the normal limit of 10.0 nmol/L during the clinical detection of distant metastases. These results indicate the usefulness of measuring serum 5-S-cysteinyl-dopa levels at initial hospital visit and during follow up for early and effective therapeutic interventions using newly developed molecular targeted drugs.
キーワード 5-S-cysteinyl-dopa biomarker lactate dehydrogenase malignant melanoma serum 5-S-CD
備考 学位審査副論文
発行日 2017-04
出版物タイトル Journal of Dermatology
44巻
4号
出版者 Wiley-Blackwell
開始ページ 449
終了ページ 454
ISSN 03852407
NCID AA00696658
資料タイプ 学術雑誌論文
言語 English
OAI-PMH Set 岡山大学
著作権者 https://creativecommons.org/licenses/by-nc-nd/4.0/deed.ja
論文のバージョン author
PubMed ID 27786364
DOI 10.1111/1346-8138.13651
Web of Sience KeyUT 000398690600029
関連URL isVersionOf https://doi.org/10.1111/1346-8138.13651